https://www.alzheimers.org.uk/news/2026-03-20/nice-reviewing-lecanemab-and-donanemab
Our comment about NICE reviewing the case for lecanemab and donanemab | Alzheimer's Society
Alzheimer's Society welcomes the decision and says the Government must be ambitious about preparing for new treatments.
the case forabout nice
https://dbem.org/donanemab/
Donanemab – Alzheimer’s Research - Donanemab And Treatment Breakthroughs
Jul 18, 2023 - Donanemab represents a significant stride in Alzheimer's treatment. The results of Eli Lilly's trial, known as TRAILBLAZER ALZ-2, confirm that donanemab was...
research and treatmentdonanemabbreakthroughs
https://www.biospace.com/unique-trial-design-expected-to-be-focus-of-upcoming-donanemab-adcomm
Unique Trial Design Expected to be Focus of Upcoming Donanemab Adcomm - BioSpace
Mar 12, 2024 - The FDA plans to convene an advisory committee meeting to discuss the safety profile and efficacy of Eli Lilly’s Alzheimer’s candidate, the company announced...
trial designto be
https://www.alz.org/alzheimers-dementia/treatments/donanemab
Donanemab Approved for Treatment of Early Alzheimer’s | alz.org
Donanemab (Kisunla™) has received traditional approval from the U.S. Food and Drug Administration (FDA) to treat early Alzheimer's disease.
donanemabapprovedtreatmentearlyalz